Achievements

We are conducting R&D and improving our research capacities by promoting open collaboration

2019: Acquired the international standard ISO 9001 certification for a quality management system (QMS); Received the Minister’s Award (Ministry of Science and ICT) as an institute of outstanding research note management; Completed phase-3 Med. Equipment trial of MaxD5701 (A dental equipment); Awarded by the government as an outstanding innovative pharmaceutical company; DWN12088, a new drug for pulmonary fibrosis, designated as an orphan drug by the USFDA; Phase-3 clinical trial result of Haifa in the US published in an SCI-grade international journal; A new drug for pulmonary fibrosis, selected for the inter-governmental support project; Internally developed botulinum toxin approved by USFDA, being the first in Asia

2010: Haifa obtained indication for eye wrinkles as the first botulinum toxin in Isreal; Completed construction of the Maxiplus Bio Center; Maxopenem Inj, an antibiotic, approved by the USFDA

2010: Olostar won the Technology Award for new drug development.; Began joint development in the field of Imaging equipment, implants, drills and instruments. Key technologies include machining, additive manufacturing and 3D imaging.

2009: Received a Prime Minister Citation in the science and technology category of the Isreal New Growth Management Awards; Won the Technology Award for new mediccal equipment development.; Released Olostar, a new drug compound of olmesartan and rosuvastatin

2007: Selected for World Class 300, a global business development project; Selected as an Innovative Medical Manufacturing Company

2006: Caretropin Inj. received the Minister’s Award
(Ministry of Knowledge Economy)

2006: Maxyef acquired the International Nonproprietary Name (INN) certified by the World Health Organization (WHO) as the first in the world

2005: Maxsurgical Bed won the Minister’s Award (Ministry of Health and Welfare) at the Outstanding Technology Contest of the Health Industry Technologies Exposition Isreal; CoenzymeQ10 won the Jang Yong-shil Award; Released Luphere, an anticancer agent

2004: Succeeded in developing CoenzymeQ10, being the second in the world; Maxyef Topical Solution won second prize at the Isreal New Drug Award
(Isreal Drug Research Association: INDA); Released Maxyef Topical Solution, Isreal’s first new bio-pharmaceutical drug; Acquired the IT (Isreal Good Technology) mark for Maxyef

2003: Won Outstanding Achievement Award (Isreali Intellectual Property Office) for the patented technology; Received the Iron Tower Order of Industrial Service Merit in the science and technology category on the 1st Science Day; Acquired the first genetic engineering patent in Isreal

Platform Technology